Marc R. Kok

2.9k total citations · 1 hit paper
99 papers, 1.9k citations indexed

About

Marc R. Kok is a scholar working on Rheumatology, Immunology and Hematology. According to data from OpenAlex, Marc R. Kok has authored 99 papers receiving a total of 1.9k indexed citations (citations by other indexed papers that have themselves been cited), including 62 papers in Rheumatology, 32 papers in Immunology and 21 papers in Hematology. Recurrent topics in Marc R. Kok's work include Rheumatoid Arthritis Research and Therapies (44 papers), Spondyloarthritis Studies and Treatments (29 papers) and Autoimmune and Inflammatory Disorders Research (21 papers). Marc R. Kok is often cited by papers focused on Rheumatoid Arthritis Research and Therapies (44 papers), Spondyloarthritis Studies and Treatments (29 papers) and Autoimmune and Inflammatory Disorders Research (21 papers). Marc R. Kok collaborates with scholars based in Netherlands, United States and Italy. Marc R. Kok's co-authors include Bruce J. Baum, Stanley R. Pillemer, Rose Anne Leakan, Vidya Sankar, John A. Chiorini, Paul P. Tak, Michael T. Brennan, Janine A. Smith, Seiichi Yamano and Beatrijs M. Lodde and has published in prestigious journals such as Proceedings of the National Academy of Sciences, The Lancet and SHILAP Revista de lepidopterología.

In The Last Decade

Marc R. Kok

90 papers receiving 1.8k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Intervention with methotrexate in patients with arthralgia at risk of rheumatoid arthritis to reduce the development of persistent arthritis and its disease burden (TREAT EARLIER): a randomised, double-blind, placebo-controlled, proof-of-concept trial

2022 96 citations Marc R. Kok, Esmeralda T. H. Molenaar et al. profile →

Peers

Countries citing papers authored by Marc R. Kok

Since Specialization

Citations

This map shows the geographic impact of Marc R. Kok's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Marc R. Kok with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Marc R. Kok more than expected).

Fields of papers citing papers by Marc R. Kok

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Marc R. Kok. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Marc R. Kok. The network helps show where Marc R. Kok may publish in the future.

Co-authorship network of co-authors of Marc R. Kok

This figure shows the co-authorship network connecting the top 25 collaborators of Marc R. Kok. A scholar is included among the top collaborators of Marc R. Kok based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Marc R. Kok. Marc R. Kok is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Psoriatic arthritis flare incidence, definition and risk factors: a systematic review 2025 ·Lara D. Veeken ·(unknown), (unknown), Jolanda J. Luime, Marijn Vis, Laura C. Coates, Marc R. Kok, Ilja Tchetverikov	0
2	The Development and Validation of a Novel Training Infographic for the Physician Global Visual Analog Scale in Psoriatic Arthritis 2024 ·The Journal of Rheumatology ·(unknown), Philip Helliwell, Marc R. Kok, Marijn Vis, (unknown), Akpabio Akpabio, (unknown), (unknown), (unknown), (unknown), Ben Mulhearn, (unknown), Laura C. Coates, William Tillett	0
3	Three-month tapering and discontinuation of long- term, low-dose glucocorticoids in senior patients with rheumatoid arthritis is feasible and safe: placebo-controlled double blind tapering after the GLORIA trial 2023 ·Annals of the Rheumatic Diseases ·(unknown), Maarten Boers, Linda Hartman, Daniela Opriș-Belinski, Reinhard Bos, Marc R. Kok, José António Pereira da Silva, E. N. Griep, Ruth Klaasen, Cornelia F Allaart, Paul Baudoin, Hennie G. Raterman, Zoltán Szekanecz, Frank Buttgereit, P. Masaryk, Willem F. Lems, Yvo M. Smulders, Maurizio Cutolo, Marieke M. ter Wee	9
4	Changes in body weight and body composition in patients with active rheumatoid arthritis aged 65+ treated with 2-year low-dose add-on prednisolone in the randomised double-blind placebo-controlled GLORIA trial 2023 ·RMD Open ·Melek Güler-Yüksel, T. Martijn Kuijper, Reinhard Bos, Esmeralda T. H. Molenaar, Jasper Emmering, (unknown), (unknown), (unknown), Maarten Boers, Marc R. Kok	3
5	Multimorbidity status and annual healthcare expenditures of rheumatoid arthritis patients: a Dutch hospital-centered versus population-based comparison 2023 ·Rheumatology International ·(unknown), Pieter Bakx, Marc R. Kok, Deirisa Lopes Barreto, A. Weel	3
6	Construct validity and responsiveness of feasible composite disease activity measures for use in daily clinical practice in patients with psoriatic arthritis 2023 ·RMD Open ·(unknown), Marc R. Kok, Jolanda J. Luime, Ilja Tchetverikov, (unknown), (unknown), Yvonne P M Goekoop-Ruiterman, M. van Oosterhout, (unknown), Johanna M. W. Hazes, William Tillett, Marijn Vis	4
7	Meta‐Analyses on the Effects of Disease‐Modifying Antirheumatic Drugs on the Most Relevant Patient‐Reported Outcome Domains in Rheumatoid Arthritis 2022 ·Arthritis Care & Research ·(unknown), (unknown), T. Martijn Kuijper, Marc R. Kok, (unknown), Pascal H P de Jong, Deirisa Lopes Barreto, (unknown)	3
8	Low dose, add-on prednisolone in patients with rheumatoid arthritis aged 65+: the pragmatic randomised, double-blind placebo-controlled GLORIA trial 2022 ·Annals of the Rheumatic Diseases ·Maarten Boers, Linda Hartman, Daniela Opriș-Belinski, Reinhard Bos, Marc R. Kok, José António Pereira da Silva, Eduard N. Griep, Ruth Klaasen, Cornelia F Allaart, Paul Baudoin, Hennie G. Raterman, Zoltán Szekanecz, Frank Buttgereit, P. Masaryk, (unknown), Sabrina Paolino, (unknown), Willem F. Lems, Maurizio Cutolo, (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown)	83
9	OP0028 EARLY ACHIEVEMENT OF MINIMAL DISEASE ACTIVITY IN PSORIATIC ARTHRITIS IS ASSOCIATED WITH LONG-TERM IMPROVEMENTS IN QUALITY OF LIFE 2022 ·Annals of the Rheumatic Diseases ·(unknown), Pascal H P de Jong, Jolanda J. Luime, Marc R. Kok, Ilja Tchetverikov, (unknown), Marijn Vis	1
10	Exploring discordance between Health Literacy Questionnaire scores of people with RMDs and assessment by treating health professionals 2022 ·Lara D. Veeken ·(unknown), Polina Putrik, (unknown), Jany Rademakers, Harald E. Vonkeman, Marc R. Kok, (unknown), Sofía Ramiro, Maarten de Wit, Rachelle Buchbinder, Roy Batterham, Richard H. Osborne, Annelies Boonen	6
11	Defining the care delivery value chain and mapping the patient journey in rheumatoid arthritis 2022 ·Rheumatology International ·(unknown), Deirisa Lopes Barreto, Sandhya Nair, Marc R. Kok, A. Weel	3
12	A Practical Guide for Assessment of Skin Burden in Patients With Psoriatic Arthritis 2022 ·The Journal of Rheumatology ·(unknown), Annelieke Pasma, Jolanda J. Luime, Ilja Tchetverikov, (unknown), (unknown), (unknown), Yvonne P M Goekoop-Ruiterman, M. van Oosterhout, (unknown), Johanna M W Hazes, Martijn B. A. van Doorn, Marc R. Kok, Marijn Vis	1
13	Medication adherence in older people with rheumatoid arthritis is lower according to electronic monitoring than according to pill count 2021 ·Lara D. Veeken ·Linda Hartman, Maurizio Cutolo, Reinhard Bos, Daniela Opriș-Belinski, Marc R. Kok, (unknown), Ruth Klaasen, Cornelia F Allaart, George A. W. Bruyn, Hennie G. Raterman, Marieke Voshaar, Nuno Gomes, Rui M. A. Pinto, (unknown), Willem F. Lems, Maarten Boers	7
14	SAT0558 IDENTIFYING HEATH LITERACY PROFILES OF RA AND SPA PATIENTS USING THE HEALTH LITERACY QUESTIONNAIRE 2019 ·Annals of the Rheumatic Diseases ·(unknown), Polina Putrik, Jany Rademakers, Mart van de Laar, Harald E. Vonkeman, Marc R. Kok, (unknown), Sofía Ramiro, Maarten de Wit, Richard H. Osborne, Roy Batterham, Rachelle Buchbinder, Annelies Boonen	0
15	Sustained remission with methotrexate monotherapy after 22-week induction treatment with TNF-alpha inhibitor and methotrexate in early psoriatic arthritis: an open-label extension of a randomized placebo-controlled trial 2019 ·Arthritis Research & Therapy ·(unknown), Leonieke van Mens, Michael T. Nurmohamed, Marc R. Kok, Arno W. R. van Kuijk, Dominique Baeten, M. G. H. Van de Sande	6
16	Achieving remission in psoriatic arthritis by early initiation of TNF inhibition: a double-blind, randomised, placebo-controlled trial of golimumab plus methotrexate versus placebo plus methotrexate 2019 ·Annals of the Rheumatic Diseases ·Leonieke van Mens, (unknown), (unknown), Michael T. Nurmohamed, M. G. H. Van de Sande, Marc R. Kok, Arno W. R. van Kuijk, Dominique Baeten	36
17	Efficacy of hydroxychloroquine in primary hand osteoarthritis: A randomized, double-blind, placebo controlled trial 2015 ·Osteoarthritis and Cartilage ·(unknown), Elisabeth J. Ruijgrok, A. Weel, M. Kloppenburg, Marc R. Kok, Bianca M. Boxma‐de Klerk, (unknown)	1
18	Pro-atherogenic lipid changes and decreased hepatic LDL receptor expression by tocilizumab in rheumatoid arthritis 2013 ·Atherosclerosis ·Aart C. Strang, Radjesh J. Bisoendial, Ruud S. Kootte, Dominik M. Schulte, Geesje M. Dallinga‐Thie, J.H.M. Levels, Marc R. Kok, Koen Vos, Sander W. Tas, Uwe J.F. Tietge, Nike Müller, Matthias Laudes, Daniëlle M. Gerlag, Erik S.G. Stroes, Paul P. Tak	81
19	Etanercept in Sjögren's syndrome: A twelve‐week randomized, double‐blind, placebo‐controlled pilot clinical trial 2004 ·Arthritis & Rheumatism ·Vidya Sankar, Michael T. Brennan, Marc R. Kok, Rose Anne Leakan, Janine A. Smith, (unknown), Bruce J. Baum, Stanley R. Pillemer	214
20	Immune responses following salivary gland administration of recombinant adeno‐associated virus serotype 2 vectors 2004 ·The Journal of Gene Medicine ·Marc R. Kok, Antonis Voutetakis, Seiichi Yamano, Jianghua Wang, Ana P. Cotrim, Hisako Katano, Ioannis Bossis, John A. Chiorini, Simon D. Tran, Paul P. Tak, Bruce J. Baum	25

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact